Cannabis in Cancer Care: From Nausea Control to Potential Tumor-Fighting Properties
Cannabis has established roles in treating chemotherapy nausea and AIDS wasting, shows promise for cancer pain (possibly synergistic with opioids), and preclinical evidence suggests potential antitumor effects.
Quick Facts
What This Study Found
The review covers established and emerging roles of cannabis in cancer care. Established indications include chemotherapy-induced nausea and vomiting (dronabinol is FDA-approved for this) and anorexia associated with AIDS wasting syndrome.
For cancer-related pain, cannabinoids may be beneficial and possibly synergistic with opioid analgesics, potentially allowing lower opioid doses. Research on cannabinoids for HIV-related peripheral neuropathy suggests they may help with cancer-related neuropathic pain as well.
The review also discusses preclinical evidence that cannabinoids may have direct antitumor effects through activation of CB1 and CB2 receptors. However, clinical evidence for antitumor activity is limited. The main limitations of medical cannabinoid use are psychoactive effects and limited bioavailability.
Key Numbers
FDA-approved: dronabinol for chemotherapy nausea and AIDS wasting. Cannabis interacts with CB1 (CNS) and CB2 (immune) receptors. Potential opioid-sparing effects for cancer pain. Preclinical antitumor activity noted.
How They Did This
This is a narrative review covering the pharmacology of cannabinoids in cancer care, including their interaction with the endocannabinoid system, established clinical indications, emerging clinical applications, and preclinical antitumor data.
Why This Research Matters
Cancer patients increasingly use cannabis for symptom management, but the evidence base varies greatly by indication. This review provides a structured overview of what is established versus speculative, helping patients and clinicians make informed decisions.
The Bigger Picture
Cannabis use in oncology spans a spectrum from well-established (anti-nausea) to speculative (antitumor). This review captures the state of evidence at a time when patient interest in cannabis for cancer was rapidly growing, providing guardrails for clinicians navigating patient requests.
What This Study Doesn't Tell Us
Antitumor effects are based on preclinical data only and should not influence treatment decisions. The review does not provide systematic quality assessment of included studies. Cannabinoid bioavailability issues complicate clinical dosing. Psychoactive effects limit dose escalation.
Questions This Raises
- ?Will clinical trials confirm antitumor effects of cannabinoids?
- ?Can cannabinoid-opioid synergy meaningfully reduce opioid requirements in cancer pain?
- ?Would non-psychoactive cannabinoids like CBD offer similar benefits without the psychoactive limitations?
Trust & Context
- Key Stat:
- Established for chemotherapy nausea; possible opioid-sparing effects for cancer pain
- Evidence Grade:
- This is a narrative review combining well-established clinical evidence (nausea) with emerging clinical (pain) and preclinical (antitumor) data.
- Study Age:
- Published in 2015. Clinical research on cannabis in oncology has continued to expand.
- Original Title:
- Cannabis in cancer care.
- Published In:
- Clinical pharmacology and therapeutics, 97(6), 575-86 (2015)
- Authors:
- Abrams, D I(2), Guzman, M
- Database ID:
- RTHC-00900
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis cure cancer?
No. While preclinical studies show some cannabinoids can slow tumor growth in laboratory settings, this has not been demonstrated in human clinical trials. Cannabis should be considered as supportive care (managing symptoms) rather than a cancer treatment.
How might cannabis work with opioids for cancer pain?
Cannabinoids and opioids act on different pain pathways that may interact synergistically. Some studies suggest that adding cannabinoids allows effective pain control at lower opioid doses, potentially reducing opioid side effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00900APA
Abrams, D I; Guzman, M. (2015). Cannabis in cancer care.. Clinical pharmacology and therapeutics, 97(6), 575-86. https://doi.org/10.1002/cpt.108
MLA
Abrams, D I, et al. "Cannabis in cancer care.." Clinical pharmacology and therapeutics, 2015. https://doi.org/10.1002/cpt.108
RethinkTHC
RethinkTHC Research Database. "Cannabis in cancer care." RTHC-00900. Retrieved from https://rethinkthc.com/research/abrams-2015-cannabis-in-cancer-care
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.